New research led by the American insurance company Anthem Inc. looked at how the SGLT-2 inhibitor drug class, which includes drugs like Invokana and Jardiance, compares to the drugs in the DPP-4 inhibitor class (such as Januvia and Tradjenta). The study found a significant reduction in heart failure hospitalizations among older patients at risk of recurrent heart failure. Read more